Great Valley Advisor Group Inc. Acquires 7,563 Shares of Novo Nordisk A/S (NYSE:NVO)

Great Valley Advisor Group Inc. boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 39.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 26,792 shares of the company’s stock after purchasing an additional 7,563 shares during the quarter. Great Valley Advisor Group Inc.’s holdings in Novo Nordisk A/S were worth $2,772,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Clarius Group LLC increased its stake in shares of Novo Nordisk A/S by 0.5% in the 4th quarter. Clarius Group LLC now owns 18,505 shares of the company’s stock valued at $1,914,000 after buying an additional 93 shares during the period. Tradewinds Capital Management LLC increased its stake in shares of Novo Nordisk A/S by 2.0% in the 4th quarter. Tradewinds Capital Management LLC now owns 4,955 shares of the company’s stock valued at $513,000 after buying an additional 95 shares during the period. Relyea Zuckerberg Hanson LLC increased its stake in shares of Novo Nordisk A/S by 3.2% in the 4th quarter. Relyea Zuckerberg Hanson LLC now owns 3,159 shares of the company’s stock valued at $327,000 after buying an additional 99 shares during the period. Fort Washington Investment Advisors Inc. OH increased its stake in shares of Novo Nordisk A/S by 3.5% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 2,960 shares of the company’s stock valued at $306,000 after buying an additional 100 shares during the period. Finally, Highlander Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 0.4% in the 4th quarter. Highlander Capital Management LLC now owns 25,100 shares of the company’s stock worth $2,597,000 after purchasing an additional 100 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 4.1 %

NYSE:NVO opened at $123.97 on Friday. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $556.32 billion, a PE ratio of 45.83, a price-to-earnings-growth ratio of 2.16 and a beta of 0.43. The firm’s 50 day moving average is $127.21 and its 200 day moving average is $112.77. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The company had revenue of $9.51 billion for the quarter, compared to analysts’ expectations of $9.14 billion. Sell-side analysts expect that Novo Nordisk A/S will post 3.32 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on NVO shares. UBS Group started coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating on the stock. Morgan Stanley began coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price on the stock. BMO Capital Markets began coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 target price on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.